Respir Med Case Rep . Successful treatment of prolonged COVID-19 with Bamlanivimab in a patient with severe B-Cell aplasia due to treatment with an anti-CD20 monoclonal antibody: A case report

[tetano]

Respir Med Case Rep


. 2021;34:101560.
doi: 10.1016/j.rmcr.2021.101560. Epub 2021 Nov 29.
Successful treatment of prolonged COVID-19 with Bamlanivimab in a patient with severe B-Cell aplasia due to treatment with an anti-CD20 monoclonal antibody: A case report


Ayham Daher ¹ , Tobias Müller ¹ , Jens Spiesshoefer ¹ , Michael Dreher ¹ , Jens Panse ²



Affiliations

• PMID: 34868871
• PMCID: PMC8628608
• DOI: 10.1016/j.rmcr.2021.101560

Abstract

A 71-year-old female patient with B-cell depletion due to treatment with an anti-CD20 monoclonal antibody was admitted for worsening COVID-19. Overall, she had persistent viral shedding, worsening respiratory failure, and progressive pneumonia that did not improve despite dexamethasone and antibiotic therapy. After administration of bamlanivimab, a monoclonal antibody with high affinity for the receptor-binding domain of the SARS-CoV-2 spike protein, inflammatory markers rapidly decreased, SARS-CoV2 RT-PCR became negative, and the patient improved clinically and radiologically. In conclusion, we demonstrated successful treatment of prolonged COVID-19 in a patient with severe B-cell aplasia with a virus-neutralizing monoclonal antibody.

Keywords: B-Cell aplasia; BMI, body-mass index; COVID-19; COVID-19, Coronavirus Disease 2019; CRP, C-reactive protein; CT, computed tomography; ICU, intensive care unit; IL-2, interleukin 2; Immunodeficiency; Monoclonal antibodies; NK, natural killer; SARS-CoV-2, severe acute respiratory syndrome coronavirus type 2; TNF-alpha, Tumor necrosis factor.